Einar Krogsaeter, PhD
Postdoctoral Scholar
Business Service Ctr
Chancellor/EVC/FAS

Unfortunately, there are generally speaking no curative therapies available, so novel therapeutic options are in high demand.

The last few years brought about techniques which should prove revolutionary in understanding neurodegeneration. While it was long impossible to obtain human nerve cells, the advent of human induced pluripotent stem cells (iPSCs) gives us access to cells of limited accessibility. Furthermore, gene editing tools (such as the gene scissors CRISPR/Cas9) provide an exciting opportunity to research diseases of interest. Upon combining iPSC technology and gene editing, scientists now have complete access to diseased human neurons, allowing us to research neurodegeneration in the optimal model system.

Combination of iPSC technology and gene editingi tools with global profiling approaches (the so-called "-omics" field, including proteomics, metabolomics, and transcriptomics) permits a broad, unbiased inquisition of pathology and revelation of druggable targets. As an avid pharmacologist and pathway biologist, I harness these techniques to develop new therapies for neurodegenerative disorders. I believe that now, as the tools required for such a venture are available, a cure for neurodegeneration is in sight - And I am thrilled to be part of it.

• Endolysosomal cation channels point the way towards precision medicine of cancer and infectious diseases.
  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2022 Chen CC, Krogsaeter E, Kuo CY, Huang MC, Chang SY, Biel M
• TRPMLs and TPCs: Targets for lysosomal storage and neurodegenerative disease therapy?
  Cell calcium 2022 Krogsaeter E, Rosato AS, Grimm C
• Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype.
  EMBO molecular medicine 2021 Soldati C, Lopez-Fabuel I, Wanderlingh LG, Garcia-Macia M, Monfregola J, Esposito A, Napolitano G, Guevara-Ferrer M, Scotto Rosato A, Krogsaeter EK, Paquet D, Grimm CM, Montefusco S, Braulke T, Storch…
• JPT2: The missing link between intracellular Ca2+ release channels and NAADP?
  Cell calcium 2021 Krogsaeter E, Tang R, Grimm C
• Human genome diversity data reveal that L564P is the predominant TPC2 variant and a prerequisite for the blond hair associated M484L gain-of-function effect.
  PLoS genetics 2021 Böck J, Krogsaeter E, Passon M, Chao YK, Sharma S, Grallert H, Peters A, Grimm C
• Two-pore and TRP cation channels in endolysosomal osmo-/mechanosensation and volume regulation.
  Biochimica et biophysica acta. Molecular cell research 2020 Chen CC, Krogsaeter E, Grimm C
• TRPML2 is an osmo/mechanosensitive cation channel in endolysosomal organelles.
  Science advances 2020 Chen CC, Krogsaeter E, Butz ES, Li Y, Puertollano R, Wahl-Schott C, Biel M, Grimm C
• Discovery of lipophilic two-pore channel agonists.
  The FEBS journal 2020 Gerndt S, Krogsaeter E, Patel S, Bracher F, Grimm C
• Evolutionary Aspects of TRPMLs and TPCs.
  International journal of molecular sciences 2020 Jaslan D, Böck J, Krogsaeter E, Grimm C
• Agonist-mediated switching of ion selectivity in TPC2 differentially promotes lysosomal function.
  eLife 2020 Gerndt S, Chen CC, Chao YK, Yuan Y, Burgstaller S, Scotto Rosato A, Krogsaeter E, Urban N, Jacob K, Nguyen ONP, Miller MT, Keller M, Vollmar AM, Gudermann T, Zierler S, Schredelseker J, Schaefer M, …
• Selective agonist of TRPML2 reveals direct role in chemokine release from innate immune cells.
  eLife 2018 Plesch E, Chen CC, Butz E, Scotto Rosato A, Krogsaeter EK, Yinan H, Bartel K, Keller M, Robaa D, Teupser D, Holdt LM, Vollmar AM, Sippl W, Puertollano R, Medina D, Biel M, Wahl-Schott C, Bracher F, …
• The protein interaction networks of mucolipins and two-pore channels.
  Biochimica et biophysica acta. Molecular cell research 2018 Krogsaeter EK, Biel M, Wahl-Schott C, Grimm C